论文部分内容阅读
目的 :探讨重组人生长激素(rhGH)治疗胃肠黏膜损伤的临床效果及对患者肠黏膜屏障、血浆表皮生长因子(EGF)和内毒素的影响。方法 :选取我院于2014年6月~2015年6月收治的100例胃肠黏膜损伤患者随机分为实验组和对照组,根据应用重组人生长激素与否分为rhGH实验组和对照组,每组50例。对照组采用常规治疗,实验组在此基础上皮下注射0.1 IU/kg/d,每日一次,连续治疗十天。观察两组治疗效果,于治疗第1、4、7、10天抽取患者血液检测二胺氧化酶(DAO)、D-乳酸、血浆EGF和血浆内毒素水平变化。结果 :实验组治疗总有效率为90%,明显高于对照组的76%,对比差异有统计学意义;实验组病人外周血DAO、D-乳酸水平和血浆内毒素水平在第1、4天无显著性差异,而在第7和10天显著低于对照组;血浆表皮生长因(EGF)在第1天无显著性差异,而在第4、7、10天显著高于对照组;随着治疗天数逐增,实验组DAO、D-乳酸和内毒素呈下降趋势,EGF呈上升趋势,对比差异有统计学意义。结论 :重组人生长激素治疗胃肠黏膜损伤患者,总有效率高,可促进肠黏膜屏障的恢复,降低内毒素水平和促进表皮生长因子分泌,疗效显著值得推广。
Objective: To investigate the clinical effect of recombinant human growth hormone (rhGH) on gastrointestinal mucosal injury and its effect on intestinal mucosal barrier, plasma epidermal growth factor (EGF) and endotoxin in patients. Methods: A total of 100 patients with gastrointestinal mucosal injury admitted from June 2014 to June 2015 in our hospital were randomly divided into experimental group and control group. According to the application of recombinant human growth hormone or not, rhGH experimental group and control group were divided into two groups. 50 cases in each group. The control group was treated routinely. The experimental group was injected subcutaneously with 0.1 IU / kg / d on this basis once a day for 10 consecutive days. The therapeutic effects of the two groups were observed. The blood samples were collected on the 1st, 4th, 7th and 10th days of treatment to detect the changes of DAO, D-lactic acid, plasma EGF and plasma endotoxin levels. Results: The total effective rate of the experimental group was 90%, which was significantly higher than 76% of the control group, the difference was statistically significant; DAO, D-lactate levels and plasma endotoxin levels in peripheral blood of patients in the experimental group were significantly higher than those of the control group There was no significant difference between the two groups at 7th and 10th days, however, the level of epidermal growth factor (EGF) was not significantly different on the 1st day, With the increase of treatment days, the DAO, D-lactate and endotoxin in the experimental group showed a decreasing trend, and the EGF showed an increasing trend, the difference was statistically significant. Conclusion: Recombinant human growth hormone treatment of patients with gastrointestinal mucosal injury, the total effective rate can promote the recovery of intestinal mucosal barrier, reduce endotoxin levels and promote the secretion of epidermal growth factor, the remarkable effect worth promoting.